No Data
Hubei Biocause Pharmaceutical (000627.SZ): The controlling subsidiary CHINA BEST Life Insurance accumulated original insurance premium income of about 8.035 billion yuan from January to February.
Gelonghui, March 14丨Hubei Biocause Pharmaceutical (000627.SZ) announced that its holding subsidiary CHINA BEST Life Insurance Co., Ltd. is promoting business development according to the overall idea of "steadfast transformation and development, highlighting value growth, comprehensively enhancing capabilities, and moving towards mature insurance companies," deeply cultivating value business, and continuously promoting business structure optimization. From January 1, 2025, to February 28, 2025, the cumulative original insurance premium income is approximately 8034.6602 million RMB.
Hubei Biocause Pharmaceutical (000627.SZ) subsidiary CHINA BEST Life Insurance had premium income of approximately 4.936 billion yuan in January.
Hubei Biocause Pharmaceutical (000627.SZ) issued an announcement that the company's holding subsidiary CHINA BEST Life Insurance Co., Ltd. according to...
Private Companies Among Hubei Biocause Pharmaceutical Co., Ltd.'s (SZSE:000627) Largest Shareholders, Saw Gain in Holdings Value After Stock Jumped 7.4% Last Week
Tianmao Group: Tianmao Group 2024 Annual Results Forecast
Biocause Pharmaceutical's Insurance Arm Accumulates 35 Billion Yuan in 2024 Insurance Premium Income
Hubei Biocause Pharmaceutical (000627.SZ): CHINA BEST Life Insurance's cumulative original insurance premium income in 2024 is approximately 34.639 billion yuan.
Hubei Biocause Pharmaceutical (000627.SZ) issued an announcement that its holding subsidiary CHINA BEST Life Insurance Co., Ltd. 20...